Download PDF
Horm Metab Res 2018; 50(10): 754-760
DOI: 10.1055/a-0733-7768
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

Bone Mineral Density is Unaltered in Women with Polycystic Ovary Syndrome

Mohd Ashraf Ganie
1   All India Institute of Medical Sciences New Delhi, Endocrinology and Metabolism Ansari Nagar, New Delhi, India
,
Semanti Chakraborty
1   All India Institute of Medical Sciences New Delhi, Endocrinology and Metabolism Ansari Nagar, New Delhi, India
,
Ashish Sehgal
2   Sher-i-Kashmir Institute of Medical Sciences, Endocrinology, Srinagar, Jammu & Kashmir, India
,
M. Sreejith
1   All India Institute of Medical Sciences New Delhi, Endocrinology and Metabolism Ansari Nagar, New Delhi, India
,
Devasenathipathy Kandasamy
1   All India Institute of Medical Sciences New Delhi, Endocrinology and Metabolism Ansari Nagar, New Delhi, India
,
Manisha Jana
1   All India Institute of Medical Sciences New Delhi, Endocrinology and Metabolism Ansari Nagar, New Delhi, India
,
Aafia Rashid
2   Sher-i-Kashmir Institute of Medical Sciences, Endocrinology, Srinagar, Jammu & Kashmir, India
› Author Affiliations
Further Information

Publication History

received 28 January 2018

accepted 05 September 2018

Publication Date:
12 October 2018 (online)

Also available at
    Permissions and Reprints

Abstract

Context The effects of endocrine aberrations associated with polycystic ovary syndrome (PCOS) on bone mineral density (BMD) in young women is a matter of debate.

Objectives To compare BMD in young women with PCOS to age and body mass index (BMI) matched controls and to elucidate its correlation to BMI, insulin resistance and serum testosterone.

Design and Methods We recruited 60 women with PCOS aged 14-24 years, diagnosed based on Rotterdam 2003 criteria, and 58 age matched controls. BMD was measured by dual energy X-ray absorptiometry. In addition, these subjects underwent biochemical and hormonal analysis including oral glucose tolerance test, calculation of Homeostatic Model Assessment–Insulin Resistance Index, measurement of serum thyroxine, thyrotropin, prolactin, total testosterone, dehydroepiandrosterone sulfate, follicular phase luteinizing hormone and follicle stimulating hormone.

Results There was no difference of BMD between women with PCOS and control women (1.103±0.08 vs 1.126±0.083 g/cm2; p=0.122). In subgroup analysis based on BMI, BMD in obese women with PCOS was significantly higher than their overweight and lean counterparts at lumbar spine (p<0.001), neck of femur (p=0.005) and total hip (p<0.001). BMD was not different at any site between oligomenorrheic and non-oligomenorrheic women with PCOS. It positively correlated with BMI, waist and hip circumference in women with PCOS. No correlation was found with HOMA-IR or Testosterone.

Conclusions BMI is the most important determinant of BMD in women with PCOS. BMD is not different between healthy young women and those with PCOS.

Key words

polycystic ovary syndrome - bone mineral density - dual energy X-ray absorptiometry - adolescent women - body mass index

Supplementary Material

    Supplementary material for this article is available online at http://www.thieme-connect.de/products.
  • Supplementary Material
 

  • References

  • 1 Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999; 84: 4006-4011
    CrossrefPubMedGoogle Scholar
  • 2 Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril 2016; 106: 6-15
    CrossrefPubMedGoogle Scholar
  • 3 March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010; 25: 544-551
    CrossrefPubMedGoogle Scholar
  • 4 Joshi B, Mukherjee S, Patil A, Purandare A, Chauhan S, Vaidya R. A cross-sectional study of polycystic ovarian syndrome among adolescent and young girls in Mumbai, India. Indian J Endocrinol Metab 2014; 18: 317-324
    CrossrefPubMedGoogle Scholar
  • 5 Kumar AN, Naidu JN, Satyanarayana U, Ramalingam K, Anitha M. Metabolic and Endocrine Characteristics of Indian Women with Polycystic Ovary Syndrome. Int J Fertil Steril 2016; 10: 22-28
    PubMedGoogle Scholar
  • 6 Livadas S, Pappas C, Karachalios A, Marinakis E, Tolia N, Drakou M, Kaldrymides P, Panidis D, Diamanti-Kandarakis E. Prevalence and impact of hyperandrogenemia in 1,218 women with polycystic ovary syndrome. Endocrine 2014; 47: 631-638
    CrossrefPubMedGoogle Scholar
  • 7 Shabir I, Ganie MA, Zargar MA, Bhat D, Mir MM, Jan A, Shah ZA, Jan V, Rasool R, Naqati A. Prevalence of metabolic syndrome in the family members of women with polycystic ovary syndrome from North India. Indian J Endocrinol Metab 2014; 18: 364-369
    CrossrefPubMedGoogle Scholar
  • 8 Echiburu B, Crisosto N, Maliqueo M, Perez-Bravo F, de Guevara AL, Hernandez P, Cavada G, Rivas C, Clavel A, Sir-Petermann T. Metabolic profile in women with polycystic ovary syndrome across adult life. Metabolism 2016; 65: 776-782
    CrossrefPubMedGoogle Scholar
  • 9 Ganie MA, Hassan S, Nisar S, Shamas N, Rashid A, Ahmed I, Douhat S, Mudassar S, Jan VM, Rashid F. High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syndrome in Indian adolescent women with polycystic ovary syndrome (PCOS). Gynecol Endocrinol 2014; 30: 781-784
    CrossrefPubMedGoogle Scholar
  • 10 Ganie MA, Marwaha RK, Dhingra A, Nisar S, Mani K, Masoodi S, Chakraborty S, Rashid A. Observation of phenotypic variation among Indian women with polycystic ovary syndrome (PCOS) from Delhi and Srinagar. Gynecol Endocrinol 2016; 32: 566-570
    CrossrefPubMedGoogle Scholar
  • 11 Kudesia R, Illions EH, Lieman HJ. Elevated Prevalence of Polycystic Ovary Syndrome and Cardiometabolic Disease in South Asian Infertility Patients. J Immigr Minor Health 2017; 19: 1338-1342
    CrossrefPubMedGoogle Scholar
  • 12 McCarthy TL, Centrella M. Androgen receptor activation integrates complex transcriptional effects in osteoblasts, involving the growth factors TGF-beta and IGF-I, and transcription factor C/EBPdelta. Gene 2015; 573: 129-140
    CrossrefPubMedGoogle Scholar
  • 13 Zborowski JV, Cauley JA, Talbott EO, Guzick DS, Winters SJ. Clinical Review 116: Bone mineral density, androgens, and the polycystic ovary: The complex and controversial issue of androgenic influence in female bone. J Clin Endocrinol Metab 2000; 85: 3496-3506
    CrossrefPubMedGoogle Scholar
  • 14 Stolk RP, Van Daele PL, Pols HA, Burger H, Hofman A, Birkenhager JC, Lamberts SW, Grobbee DE. Hyperinsulinemia and bone mineral density in an elderly population: The Rotterdam Study. Bone 1996; 18: 545-549
    CrossrefPubMedGoogle Scholar
  • 15 Barrett-Connor E, Kritz-Silverstein D. Does hyperinsulinemia preserve bone?. Diabetes Care 1996; 19: 1388-1392
    CrossrefPubMedGoogle Scholar
  • 16 Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991; 72: 83-89
    CrossrefPubMedGoogle Scholar
  • 17 Kumar A, Sharma AK, Mittal S, Kumar G. The relationship between body mass index and bone mineral density in premenopausal and postmenopausal north indian women. J Obstet Gynaecol India 2016; 66: 52-56
    CrossrefPubMedGoogle Scholar
  • 18 Ganie MA, Marwaha RK, Nisar S, Farooqi KJ, Jan RA, Wani SA, Gojwari T, Shah ZA. Impact of hypovitaminosis D on clinical, hormonal and insulin sensitivity parameters in normal body mass index polycystic ovary syndrome women. J Obstet Gynaecol 2016; 36: 508-512
    CrossrefPubMedGoogle Scholar
  • 19 Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25
    CrossrefPubMedGoogle Scholar
  • 20 Martin KA, Chang RJ, Ehrmann DA, Ibanez L, Lobo RA, Rosenfield RL, Shapiro J, Montori VM, Swiglo BA. Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93: 1105-1120
    CrossrefPubMedGoogle Scholar
  • 21 Misra A, Chowbey P, Makkar BM, Vikram NK, Wasir JS, Chadha D, Joshi SR, Sadikot S, Gupta R, Gulati S, Munjal YP. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physicians India 2009; 57: 163-170
    PubMedGoogle Scholar
  • 22 Adami S, Zamberlan N, Castello R, Tosi F, Gatti D, Moghetti P. Effect of hyperandrogenism and menstrual cycle abnormalities on bone mass and bone turnover in young women. Clin Endocrinol (Oxf) 1998; 48: 169-173
    CrossrefPubMedGoogle Scholar
  • 23 Berberoglu Z, Aktas A, Fidan Y, Yazici AC, Aral Y. Association of plasma GDF-9 or GDF-15 levels with bone parameters in polycystic ovary syndrome. J Bone Miner Metab 2015; 33: 101-108
    CrossrefPubMedGoogle Scholar
  • 24 Good C, Tulchinsky M, Mauger D, Demers LM, Legro RS. Bone mineral density and body composition in lean women with polycystic ovary syndrome. Fertil Steril 1999; 72: 21-25
    CrossrefPubMedGoogle Scholar
  • 25 Noyan V, Yucel A, Sagsoz N. The association of bone mineral density with insulin resistance in patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2004; 115: 200-205
    CrossrefPubMedGoogle Scholar
  • 26 Karadag C, Yoldemir T, Gogas Yavuz D. Determinants of low bone mineral density in premenopausal polycystic ovary syndrome patients. Gynecol Endocrinol 2017; 33: 234-237
    CrossrefPubMedGoogle Scholar
  • 27 Katulski K, Slawek S, Czyzyk A, Podfigurna-Stopa A, Paczkowska K, Ignaszak N, Podkowa N, Meczekalski B. Bone mineral density in women with polycystic ovary syndrome. J Endocrinol Invest 2014; 37: 1219-1224
    CrossrefPubMedGoogle Scholar
  • 28 To WW, Wong MW. A comparison of bone mineral density in normal weight and obese adolescents with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2012; 25: 248-253
    CrossrefPubMedGoogle Scholar
  • 29 Yuksel O, Dokmetas HS, Topcu S, Erselcan T, Sencan M. Relationship between bone mineral density and insulin resistance in polycystic ovary syndrome. J Bone Miner Metab 2001; 19: 257-262
    CrossrefPubMedGoogle Scholar
  • 30 Di Carlo C, Shoham Z, MacDougall J, Patel A, Hall ML, Jacobs HS. Polycystic ovaries as a relative protective factor for bone mineral loss in young women with amenorrhea. Fertil Steril 1992; 57: 314-319
    CrossrefPubMedGoogle Scholar
  • 31 Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800
    CrossrefPubMedGoogle Scholar